HWM
TGTX icon

HB Wealth Management’s TG Therapeutics TGTX Stock Holding History

HB Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$464K Buy
8,444
+930
+12% +$38.1K ﹤0.01% 1141
2026
Q1 		$250K Buy
7,514
+475
+7% +$14.2K ﹤0.01% 1324
2025
Q4 		$210K Buy
7,039
+1,060
+18% +$34.6K ﹤0.01% 1312
2025
Q3 		$216K Buy
+5,979
New +$197K ﹤0.01% 1239
2025
Q2 		– Sell
-5,816
Closed -$229K – 1295
2025
Q1 		$229K Buy
+5,816
New +$196K ﹤0.01% 1086

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

HB Wealth Management's TGTX Position: Q2 2026 in Review

HB Wealth Management increased its TG Therapeutics (TGTX) stake by 12% in Q2 2026, buying an estimated $38.1K and bringing the position to 8,444 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

HB Wealth Management first reported a position in TGTX in Q1 2025 and has held it in 5 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • HB Wealth Management held 8,444 shares of TG Therapeutics worth $464K as of Q2 2026.
  • HB Wealth Management bought 930 TG Therapeutics shares in Q2 2026, an estimated $38.1K.
  • TG Therapeutics made up ﹤0.01% of HB Wealth Management's portfolio in Q2 2026, its #1141 holding.
  • HB Wealth Management first reported a position in TG Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on HB Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.